PMC:7205724 / 1-150 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":29,"end":37},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":131,"end":146},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":29,"end":37},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":88,"end":112},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_35705"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T1","span":{"begin":131,"end":146},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A1","pred":"meddra_id","subj":"T1","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T1","span":{"begin":88,"end":105},"obj":"http://purl.obolibrary.org/obo/IDO_0000610"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T1","span":{"begin":29,"end":37},"obj":"Species"}],"attributes":[{"id":"A1","pred":"ncbi_taxonomy_id","subj":"T1","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T2","span":{"begin":39,"end":113},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1","span":{"begin":29,"end":37},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"pubann:denotes","subj":"1","obj":"MESH:C000657245"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T1","span":{"begin":7,"end":16},"obj":"NN"},{"id":"T2","span":{"begin":17,"end":25},"obj":"NN"},{"id":"T3","span":{"begin":26,"end":28},"obj":"IN"},{"id":"T4","span":{"begin":29,"end":37},"obj":"NN"},{"id":"T5","span":{"begin":37,"end":38},"obj":"-COLON-"},{"id":"T6","span":{"begin":39,"end":48},"obj":"NN"},{"id":"T7","span":{"begin":49,"end":52},"obj":"CC"},{"id":"T8","span":{"begin":53,"end":63},"obj":"NN"},{"id":"T9","span":{"begin":64,"end":67},"obj":"IN"},{"id":"T10","span":{"begin":68,"end":71},"obj":"DT"},{"id":"T11","span":{"begin":72,"end":75},"obj":"NN"},{"id":"T12","span":{"begin":76,"end":78},"obj":"IN"},{"id":"T13","span":{"begin":79,"end":87},"obj":"JJ"},{"id":"T14","span":{"begin":88,"end":105},"obj":"JJ"},{"id":"T15","span":{"begin":106,"end":112},"obj":"NNS"},{"id":"T16","span":{"begin":112,"end":113},"obj":"-COLON-"},{"id":"T17","span":{"begin":114,"end":129},"obj":"NNS"},{"id":"T18","span":{"begin":129,"end":130},"obj":"-COMMA-"},{"id":"T19","span":{"begin":131,"end":146},"obj":"NNS"},{"id":"T20","span":{"begin":146,"end":147},"obj":"-COMMA-"}],"relations":[{"id":"R1","pred":"arg1Of","subj":"T2","obj":"T1"},{"id":"R2","pred":"arg1Of","subj":"T2","obj":"T3"},{"id":"R3","pred":"arg2Of","subj":"T4","obj":"T3"},{"id":"R4","pred":"arg1Of","subj":"T2","obj":"T5"},{"id":"R5","pred":"arg1Of","subj":"T6","obj":"T7"},{"id":"R6","pred":"arg2Of","subj":"T8","obj":"T7"},{"id":"R7","pred":"arg1Of","subj":"T7","obj":"T9"},{"id":"R8","pred":"arg2Of","subj":"T11","obj":"T9"},{"id":"R9","pred":"arg1Of","subj":"T11","obj":"T10"},{"id":"R10","pred":"arg1Of","subj":"T11","obj":"T12"},{"id":"R11","pred":"arg2Of","subj":"T15","obj":"T12"},{"id":"R12","pred":"arg1Of","subj":"T15","obj":"T13"},{"id":"R13","pred":"arg1Of","subj":"T15","obj":"T14"},{"id":"R14","pred":"arg1Of","subj":"T7","obj":"T16"},{"id":"R15","pred":"arg1Of","subj":"T17","obj":"T18"},{"id":"R16","pred":"arg2Of","subj":"T19","obj":"T18"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T1","span":{"begin":131,"end":146},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T1","span":{"begin":29,"end":37},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}

{"project":"LitCovid-sentences","denotations":[{"id":"T2","span":{"begin":39,"end":113},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"owards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, a"}